CSS LLC’s PharmaCyte Biotech PMCB Stock Holding History

CSS LLC’s Portfolio PMCB Stock Details PMCB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-13,186	Closed	-$27.7K	–	904
2023 Q3	$27.7K	Hold	13,186	–	–	﹤0.01%	750
2023 Q2	$37.7K	Buy	+13,186	New	+$39.6K	﹤0.01%	793

Other funds holding PMCB

KPF

K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EPM

Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

CSS LLC's PMCB Position: Q4 2023 in Review

CSS LLC sold out of PharmaCyte Biotech (PMCB) in Q4 2023, closing a stake of 13,186 shares — an estimated $27.7K sold.

CSS LLC first reported a position in PMCB in Q2 2023 and held it in 2 quarters. The position peaked at $37.7K in Q2 2023. 32 funds tracked by Wall St. Rank hold PMCB as of Q4 2023.

CSS LLC reported no remaining PharmaCyte Biotech position as of Q4 2023 after selling out during the quarter.
CSS LLC sold 13,186 PharmaCyte Biotech shares in Q4 2023, an estimated $27.7K.
CSS LLC first reported a position in PharmaCyte Biotech in Q2 2023 and held it in 2 quarters.
CSS LLC's PharmaCyte Biotech position peaked at $37.7K in Q2 2023.
32 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q4 2023.

Based on CSS LLC's 13F filing for Q4 2023, filed 14 Feb 2024.